title: Hypercoagulopathy after repeated injection of 5% ethanolamine oleate to sclerose esophageal varices.
abstract: Hematological and coagulating parameters were examined in 53 patients in an attempt to find possible evidence of disseminated intravascular coagulation after intravascular injection of 5% ethanolamine oleate to sclerose esophageal varices. FDP-E in the peripheral blood measured by latex photometric immunoassay significantly increased from 111.2 +/- 112.9 to 234.2 +/- 178.3 ng/ml and 370.4 +/- 189.5 ng/ml one hour after the first and second sessions of sclerotherapy, respectively (p less than 0.01). The other parameters showed no significant change, except on the first day after sclerotherapy. The increase of FDP-E was closely related to fibrinopeptide A (r = 0.689, p less than 0.01) and fibrinogen (r = 0.585, p less than 0.05), before the sclerotherapy. As repeated intravariceal sclerotherapy over short time intervals can lead to a deterioration of the coagulating system, especially in patients with abnormal preoperative coagulopathy, latex photometric immunoassay for FDP-E is a rapid and useful method of monitoring alterations in the coagulating system.
authors.affiliation: Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Hashizume
authors.forename: H
authors.initials: H
authors.lastname: Yamaga
authors.forename: S
authors.initials: S
authors.lastname: Kitano
authors.forename: K
authors.initials: K
authors.lastname: Sugimachi
mesh_terms: D000328:Adult; D000368:Aged; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D004211:Disseminated Intravascular Coagulation / Q000139:chemically induced; D004932:Esophageal and Gastric Varices / Q000150:complications / Q000628:therapy*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005344:Fibrinopeptide A / Q000032:analysis; D005345:Fibrinopeptide B / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009829:Oleic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D012597:Sclerosing Solutions / Q000009:adverse effects*
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; D009829:Oleic Acids; D012597:Sclerosing Solutions; D005344:Fibrinopeptide A; D005345:Fibrinopeptide B; C033343:ethanolamine oleate